Informations générales (source: ClinicalTrials.gov)
Prevalence of Psychocognitive Impairments in Adolescents Surviving Childhood Leukemia : LEA-PsyCog (LEA-PsyCog)
Interventional
N/A
Assistance Publique Hopitaux De Marseille (Voir sur ClinicalTrials)
juillet 2013
juin 2016
29 juin 2024
The objective of the LEA-PsyCog project is to assess the prevalence of psychiatric
disorders and psychocognitive impairments in adolescents surviving childhood leukemia .
The second objective is to explore the complex relationships between psycocognitive
development and soiciodemodemographics data, main characteristics of leukemia,
treatments, side-effects, quality of life and characteristics of proxyies environment.
3. Materials and Methods The LEA study is based on the constitution of a multi-centric
prospective cohort in 11 university hospitals: Bordeaux, Clermont-Ferrand, Grenoble,
Lyon, Paris (Trousseau, Robert Debré, St Louis), Marseille, Montpellier, Nancy,
Nice, Rennes. Are inclued in LEA all the children diagnosed and treated for acute
leukemia since January 1980 (incident and prevalent cases), surviving at month 24
for the AML and ALL grafted in complete remission and at month 48 for the ALL not
grafted in first complete remission.
The LEA Psy-Cog study rests on a sample of the LEA cohort. Are included the patients
12-17-years-old from the PACA-Corse sub-cohort (administrative district of 4 million of
people which corresponds to the Marseille and Nice centers). Patients from this two
centers are the patients with the more important length of survey, allowing us to produce
a not biaised estimation of prevalence rate. Finally, the choice of this subsample is
supported by the proximity of the Mediterranean Center for Adolescent in Marseilles,
specifically dedicated to the psychological follow-up of children suffering from cancer.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Assistance Publique Hopitaux de Marseille - 13354 - Marseille - France | david dafonseca | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
-
- Age 18-year-old subordinate at the time of the diagnosis;
- Diagnosis of acute(sharp) leukaemia;
- Diagnosis from January, 1980;
- Treatment(Processing) of the acute(sharp) leukaemia introduced in one of the
inquiring centers (services(departments) specialized hematology and Clermont
Ferrand's pediatric oncology, Grenoble, Lyon, Marseille, Nancy, Nancy, Nice, Paris -
Robert Debré/Saint Debré/Saint Louis/Trousseau Louis/Trousseau;
- Living in France;
- Possessing a national insurance scheme
- 24-month-old Survivor of recoil(drop) with regard to(compared with) the diagnosis
for the Leukaemia Aiguës Myéloblastiques (LAM) and Leukaemia Aiguës Lymphoblastiques
( LAL) transplanted in 1st complete forgiveness; or in 48 months of recoil(drop)
with regard to(compared with) the diagnosis for the LAL not transplanted in first
complete forgiveness;
-
- Age 18-year-old subordinate at the time of the diagnosis;
- Diagnosis of acute(sharp) leukaemia;
- Diagnosis from January, 1980;
- Treatment(Processing) of the acute(sharp) leukaemia introduced in one of the
inquiring centers (services(departments) specialized hematology and Clermont
Ferrand's pediatric oncology, Grenoble, Lyon, Marseille, Nancy, Nancy, Nice, Paris -
Robert Debré/Saint Debré/Saint Louis/Trousseau Louis/Trousseau;
- Living in France;
- Possessing a national insurance scheme
- 24-month-old Survivor of recoil(drop) with regard to(compared with) the diagnosis
for the Leukaemia Aiguës Myéloblastiques (LAM) and Leukaemia Aiguës Lymphoblastiques
( LAL) transplanted in 1st complete forgiveness; or in 48 months of recoil(drop)
with regard to(compared with) the diagnosis for the LAL not transplanted in first
complete forgiveness;
- Failure to respect the criteria of inclusion beforehand quoted,
- Initial Treatment(Processing) realized except 2 participating centers (Marseille,
Nice), even in case of moving in in the geographical zones covered by these centers
during the phase of treatment(processing) or in the course of follow-up